OLIN Corp OLN

Healthcare SIC 2800 - Chemicals & Allied Products NYSE

Last close 17.37 2026-09-04
Market cap $1.98B 2026-06-30 share count
52-week range 16.73 - 30.46

Valuation FY2025 figures against the last close

P/S0.3x
P/E
P/FCF8.0x
EV/EBITDA8.8x
Dividend yield4.6%
Diluted EPS-0.88

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $6.78B$6.54B$6.83B$9.38B$8.91B$5.76B$6.11B$6.95B$6.27B$5.55B
Cost of revenue $6.28B$5.80B$5.67B$7.19B$6.62B$5.37B$5.44B$5.82B$5.55B$4.94B
Gross profit $501.5M$737.5M$1.17B$2.18B$2.29B$383.4M$670.8M$1.12B$713.5M$606.1M
SG&A $463.3M$408.5M$406.7M$393.9M$416.9M$422.0M$416.9M$430.6M$369.8M$347.2M
Operating income $5.3M$296.5M$712.1M$1.78B$1.85B-$746.7M$177.8M$676.9M$296.6M$107.8M
Interest expense $188.3M$184.5M$181.1M$143.9M$348.0M$292.7M$243.2M$243.2M$217.4M$191.9M
Pre-tax income -$161.1M$141.7M$559.3M$1.68B$1.54B-$1.02B-$36.9M$437.3M$117.2M-$34.2M
Income tax $60.0M$36.7M$107.3M$349.1M$242.0M$50.1M$25.6M$109.4M$432.3M$30.3M
Net income -$101.1M$105.0M$452.0M$1.33B$1.30B-$969.9M-$11.3M$327.9M$549.5M-$3.9M
EPS, basic -0.880.923.669.168.15-6.14-0.071.973.31-0.02
EPS, diluted -0.880.913.578.947.96-6.14-0.071.953.26-0.02
Shares, diluted (wtd. avg.) $114.6M$119.5M$128.8M$148.5M$163.0M$157.9M$162.3M$168.4M$168.5M$165.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $167.6M$175.6M$170.3M$194.0M$180.5M$189.7M$220.9M$178.8M$218.4M$184.5M
Short-term investments $0$0$0$0$0$0$0$0$0$0
Receivables $760.4M$776.3M$733.2M$675.0M
Inventory $784.5M$823.5M$858.8M$941.9M$868.3M$674.7M$695.7M$711.4M$682.6M$630.4M
Total current assets $1.97B$2.08B$1.97B$2.16B$2.25B$1.72B$1.71B$1.71B$1.70B$1.55B
Property, plant and equipment $2.20B$2.33B$2.52B$2.67B$2.91B$3.17B$3.32B$3.48B$3.58B$3.70B
Goodwill $1.43B$1.42B$1.42B$1.42B$1.42B$1.42B$2.12B$2.12B$2.12B$2.12B
Other intangibles $174.4M$206.6M$245.8M$273.8M$331.7M$399.4M$448.1M$511.6M$578.5M$629.6M
Total assets $7.33B$7.58B$7.71B$8.04B$8.52B$8.27B$9.19B$9.00B$9.22B$8.76B
Accounts payable $806.1M$861.6M$775.4M$837.7M$847.7M$729.2M$651.9M$636.5M$669.8M$570.8M
Short-term debt $109.7M$129.0M$78.8M$9.7M$201.1M$26.3M$2.1M$125.9M$700.0K$80.5M
Total current liabilities $1.63B$1.63B$1.53B$1.56B$1.68B$1.20B$1.08B$1.12B$954.3M$922.6M
Long-term debt $2.72B$2.71B$2.59B$2.57B$2.58B$3.84B$3.34B$3.10B$3.61B$3.54B
Total liabilities $5.46B$5.52B$5.44B$5.50B$5.87B$6.82B$6.77B$6.17B$6.46B$6.49B
Retained earnings $2.14B$2.36B$2.58B$2.22B$1.01B-$155.1M$941.1M$1.07B$790.3M$373.8M
Total equity $1.84B$2.02B$2.23B$2.54B$2.65B$1.45B$2.42B$2.83B$2.75B$2.27B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $474.2M$503.2M$974.3M$1.92B$1.74B$433.0M$617.3M$907.8M$648.8M$603.2M
Depreciation and amortisation $521.6M$518.1M$533.4M$598.8M$582.5M$568.4M$597.4M$601.4M$558.9M$533.5M
Stock-based compensation $20.7M$17.1M$18.6M$14.1M$8.3M$13.6M$10.7M$12.0M$9.1M$7.5M
Capital expenditure $226.3M$195.1M$236.0M$236.9M$200.6M$298.9M$385.6M$385.2M$294.3M$278.0M
Investing cash flow -$319.6M-$283.7M-$340.8M-$259.7M-$197.4M-$835.7M-$365.6M-$382.3M-$498.5M-$473.5M
Financing cash flow -$163.0M-$212.6M-$656.9M-$1.65B-$1.55B$371.0M-$209.3M-$564.8M-$116.8M-$337.5M
Dividends paid $91.6M$94.2M$101.0M$116.2M$127.8M$126.3M$129.3M$133.6M$133.0M$132.1M
Buybacks $50.5M$300.3M$711.3M$1.35B$251.9M$0$145.9M$50.0M$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000074303-26-000027.

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
SOLS Solstice Advanced Materials Inc. $10.12B 42.8x 3.1%
PRM Perimeter Solutions, Inc. $5.20B 16.4%
NGVT Ingevity Corp $2.43B -2.7%
IOSP INNOSPEC INC. $2.31B 20.1x -3.7%
CC Chemours Co $2.30B 0.4%
HUN Huntsman CORP $1.69B -5.8%
FMC FMC CORP $1.62B -18.3%
ECVT Ecovyst Inc. $1.12B 20.9%